Enter your ZIP code:

Please enter a 5 digit zipcode
No results...

Entering your zip code helps us to provide information and results that are more relevant to you.

Your privacy is important to us. By continuing, you agree to our Privacy Policy.





Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Maintenance of Effect of NBI 1065845

Neurology
Adrian Preda
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Maintenance of Effect of NBI 1065845 as an Adjunctive Treatment in Subjects with Major Depressive Disorder (MDD)
Brain - Neurologic/ Psychologic

Study Description

Eligibility

  1. Participant has a primary diagnosis of recurrent MDD (moderate or severe) or persistent depressive disorder.
  2. Participant has had an inadequate response to oral antidepressant treatments in the current episode of depression.
  3. Participant must have been taking oral antidepressants for at least 8 weeks and is willing to continue the same oral antidepressants at the same dose and frequency of administration throughout participation in the study.
  4. Total Hamilton Depression Rating Scale-17 Item (HAM-D17) score greater than or equal to 22 at screening and at study baseline (Day 1).
  5. Willing and able to comply with all study procedures and restrictions in the opinion of the investigator.

Key

  1. A current or prior psychiatric disorder diagnosis in the last 1 year that was the primary focus of treatment other than MDD.
  2. Are considered by the investigator to be at imminent risk of suicide or injury to self or others.
  3. Participants depressive symptoms have previously demonstrated nonresponse to electroconvulsive therapy (ECT) in the current major depressive episode.
A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.